SAVA is on an interesting quest for both 1. drug treatment for AZ and 2. EARLY test for AZ. The test may prove to be a billion dollar global opportunity.
The drug effort is quite different than Biogen and others have taken and has had some early encouraging results which is why the FDA is supportive of the newly approved trials. I have applied for MY grandfather to participate in the new trials.
Unlike many drug trials where half are given a placebo..relatives of patients in this trial will have no trouble telling if the drug is helping their loved one. Early 2022 could well see some anecdotal feedback leak into the Alzheimer community?
Take a look at the SAVA Board member retired from JNJ.
There is an excellent report outon SAVA from a brilliant analyst at Maxim Group.
If the small very smart team of SAVA in Austin Texas does show the results they hope in new extended trials over the next 12-18 months than a good part of our elder seniors and their families will benefit. SAVA shareholders will also do exceptionally well. IMHO
News 
Market Data 
Discover 
